28
A multicenter randomized, sham-controlled trial has found that portable oxygen concentrators did not increase daily physical activity for people living with fibrotic interstitial lung disease who desaturate only with exertion. The Lancet Respiratory Medicine study, published online on February 26, 2026, tracked step counts over three months and observed no advantage for ambulatory oxygen over ambient air delivered via an identical device. The findings land squarely in the middle of ongoing debates over how payers, regulators, and clinicians should define “meaningful benefit” from ambulatory oxygen in patients who do not meet classic long‑term oxygen therapy criteria.
What the trial tested and why it matters for patients and payers
| Study feature | Details |
|---|---|
| Condition | Fibrotic interstitial lung disease with isolated exertional hypoxemia (SpO2 ≤88% on 6‑minute walk) |
| Design and setting | Parallel-group, multicenter, randomized, sham-controlled trial across seven hospital sites in Australia and Sweden |
| Enrollment window | August 6, 2019-January 10, 2024 |
| Participants | 116 randomized (59 ambulatory oxygen; 57 sham air); mean age 71 years |
| Intervention vs. control | Portable oxygen concentrator (Inogen One G3 HF) delivering oxygen during daily activities vs. an identical device delivering air (sham) |
| Primary outcome | Change in physical activity at 3 months (mean steps/day via StepWatch activity monitor) |
| Main result | No benefit for ambulatory oxygen: between-group difference -334 steps/day (95% CI, -803 to 134) |
| Safety | No serious adverse events related to study treatments; no difference in number or type of adverse events |
| Source | Lancet Respiratory Medicine randomized, sham-controlled trial |
Key outcomes at a glance
- Physical activity: No increase in mean daily steps with ambulatory oxygen at 3 months compared with a visually identical air device, suggesting that correcting exertional desaturation alone may not be sufficient to change real‑world movement patterns.
- Adverse events: No treatment-related serious adverse events; overall event profiles were similar between groups, supporting the short‑term safety of both active and sham devices in this population.
- Population focus: People with fibrotic interstitial lung disease who do not meet resting hypoxemia criteria but desaturate with exertion-a group that frequently sits at the margins of current coverage policies.
How these findings fit within the broader evidence base
- Exercise physiology vs. day-to-day behavior: In chronic lung disease, interventions that improve exercise test performance do not always translate into higher free‑living physical activity, a pattern also seen after pulmonary rehabilitation programs. The present trial reinforces that distinction by using actigraphy rather than relying solely on lab‑based endpoints.
- Prior ILD trials: Earlier randomized studies in fibrotic interstitial lung disease have shown mixed effects for ambulatory oxygen-improving some physiologic and symptom endpoints in test settings but not consistently raising daily step counts across weeks of follow-up. This new three‑month dataset adds weight to the argument that symptom relief and behavioral change must be evaluated separately.
- Device performance constraints: Many portable concentrators use pulsed-dose delivery and have limited maximum oxygen output compared with stationary or liquid oxygen systems, which can influence real‑world efficacy for patients with high exertional oxygen needs. For regulators and purchasers, the trial highlights how device specifications and patient phenotype jointly determine whether advertised performance translates into functional gain.
Policy and coverage implications in the United States
| Policy area | Current landscape | Relevance to the trial |
|---|---|---|
| Medicare national coverage | Home oxygen coverage under National Coverage Determination (NCD) 240.2 was revised beginning in 2021-2022 to expand access for both acute and chronic conditions when medically necessary, with discretion for Medicare Administrative Contractors to determine “reasonable and necessary” use outside historical criteria, as laid out in updated CMS policy for home oxygen. | People with exertional-only hypoxemia may qualify when documentation demonstrates medical necessity, but evidence gaps on activity outcomes could shape local coverage and recertification practices, especially if payers seek objective metrics beyond symptom reports. |
| Regulatory oversight of devices | Portable oxygen generators/concentrators are regulated as Class II medical devices with performance standards under 21 CFR 868.5440 and are subject to 510(k) premarket notification and quality system requirements set by the US Food and Drug Administration. | Trial findings point to the importance of performance characteristics (e.g., pulsed vs. continuous flow, maximal output) and user acceptability in real‑world effectiveness, potentially informing future FDA review focus and post‑market surveillance priorities. |
| Utilization and DME supply | Coverage expansions occurred alongside operational pressures in the durable medical equipment sector, including supply constraints for high‑flow or liquid oxygen solutions in some regions and a long‑running shift toward lighter, portable concentrator models. | Absent step-count gains at 3 months may intensify payer focus on objective need, device selection, and appropriate outcomes (symptoms, safety, participation) for continued coverage, particularly where higher‑cost alternatives such as liquid oxygen are under pressure. |
| Documentation standards | Recent CMS transmittals emphasize clinical documentation of hypoxemia (resting or exertional), functional impact, and medical necessity, while eliminating older certificate forms in favor of medical‑record-based justification. | Trials that embed actigraphy and standardized walk testing can inform which patient-reported and physiologic endpoints are most policy-relevant, giving clinicians a clearer template for writing notes that withstand audit. |
| Primary source | The evidence arrives as Medicare contractors refine how they operationalize NCD 240.2 in coverage decisions for ambulatory oxygen, especially in borderline indications such as exertional-only hypoxemia. | |
Clinical and public‑health context
- This trial does not address the role of long‑term oxygen therapy for individuals with chronic resting hypoxemia, where established practice standards and survival data remain in place and are unlikely to be altered by these findings.
- For people with exertional-only desaturation, the absence of a step‑count benefit at three months underscores that alleviating desaturation during activity and increasing free‑living activity are related but distinct goals-raising questions about which outcome should anchor treatment decisions and coverage renewals.
- Population‑level priorities include equitable access to appropriately matched oxygen delivery systems, integration of pulmonary rehabilitation and structured activity coaching, and support for mobility and participation beyond physiologic correction alone.
- Future research needs include device innovation that reliably meets high exertional flow requirements, pragmatic endpoints that reflect daily life (including dyspnea, fatigue, and participation), and implementation strategies that pair oxygen therapy with behavioral and environmental supports to reduce activity barriers.
What stakeholders should watch
- Coverage decisions: How regional payers interpret activity-neutral findings when setting documentation and recertification requirements for ambulatory oxygen in exertional-only hypoxemia, and whether step-count or actigraphy thresholds begin to appear in local policies.
- Procurement and device choice: Whether health systems and DME suppliers adjust formularies toward devices capable of higher effective oxygen delivery during real‑world exertion, or differentiate device selection for patients with more severe exertional desaturation.
- Trial endpoints: Growing use of actigraphy-derived measures in regulatory and payer discussions about meaningful benefit for chronic respiratory conditions, and whether future ILD trials combine these digital measures with patient‑reported outcomes to better capture day‑to‑day life.
